Gene, Genomics, Genotype and In-Vitro - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene

Genomics

Genotype

In-Vitro

Osimertinib Resistance and EGFR Mutations in NSCLC Treatment

Bioengineer

JANUARY 16, 2024

In patients with T790M mutant NSCLC receiving osimertinib, 63% experienced loss of T790M at progression, commonly linked to histological transdifferentiation, KRAS mutations, or gene fusions. not reached) in genomic analysis of post-progression samples from patients receiving second-line osimertinib. months vs. 15.2 months, p = 0.01).

Genome

Genome Genomics Protein In-Vitro

Nine new industry collaborations driving drug discovery forward

Drug Discovery World

MAY 29, 2024

ERS Genomics and IRBM ERS Genomics and IRBM have signed an agreement granting IRBM access to ERS’ CRISPR/Cas9 patent portfolio. Studies have found that EBV triggers a range of very serious health conditions including certain cancers and multiple sclerosis. We see a great need for a vaccine against EBV.”

Drugs

Drugs Gene Editing Life Science Genome

Osimertinib Resistance and EGFR Mutations in NSCLC Treatment

Nine new industry collaborations driving drug discovery forward

Stay Connected